July, 2025
Regeneron Joins PETAL Consortium as a Funding Partner for Our Pathology
Initiative!
We are thrilled to announce that Regeneron Pharmaceuticals has awarded an educational grant to support PETAL Consortium’s central pathology review initiative, which leverages digital pathology to ensure the consistent and precise diagnosis of peripheral T-cell lymphoma.
Read more
Josie Ford was interviewed by Blood Cancers Today!
We're excited to share that Josie Ford was interviewed by Blood Cancers Today about her recently published study in Blood Advances, which investigates the efficacy of the drug combination duvelisib and romidepsin in patients with rare and aggressive blood cancers.
Read more
Research Spotlight: Study Demonstrates Drug Combination is Well-Tolerated, Safe and Effective for Patients with Aggressive Blood Cancer
In this research spotlight, learn about Josie Ford’s recent publication on a novel drug combination for lymphoma. She shares how the team's findings could shape future approaches to care for patients with aggressive blood cancers.
Read more
Real-World Data Study Led by Dr. Salvia Jain Highlights Promising Treatment for Aggressive Blood Cancer
A new study led by PETAL investigator Dr. Salvia Jain demonstrates that a combination of two blood cancer medications is well tolerated, safe, and effective for patients with aggressive blood cancers who do not respond to standard therapy. The research, based on real-world data, is now featured in the Mass General Brigham Newsroom.
Read more
June, 2025
Founder and Principal investigator of the PETAL Consortium
In this Q&A, meet Dr. Salvia Jain–founder and principal investigator of the PETAL Consortium–as she shares how her journey in medicine began and what inspired her to focus on blood cancer research.
Read more
May, 2025
PETAL Consortium Featured in ASCO Post!
We are excited to share that PETAL Consortium is featured in the ASCO Post! The article highlights our groundbreaking study, which reveals how a specific sequence of therapies can significantly improve survival rates for patients with relapsed/refractory T- and NK-cell lymphomas. By leveraging global data from PETAL, we are moving closer to refining treatment strategies and providing new hope for patients with limited treatment options.
Read more on: The ASCO Post
PETAL Research Featured in Mass General Brigham News
Our recent publication in the British Journal of Haematology has been featured by Mass General Brigham. The news release underscores the PETAL Consortium’s innovative and impactful research in guiding personalized treatment strategies for relapsed and refractory T- and NK-cell lymphomas.
Read the press release
Forecasting Optimal Treatments in Relapsed/Refractory Mature T- and NK-Cell Lymphomas – The PETAL Consortium’s latest paper published in the British Journal of Haematology.
Read the full paper
We are thrilled that our clinical researcher Caroline MacVicar has been accepted to and plans on attending medical school at Uniformed Services University (USU). Congratulations!
We are delighted to congratulate Dhruv Mistry, a key PETAL team member, on earning his M.B.B.S. degree. We cannot wait to see his career unfold.
April, 2025
Blood Cancers Today spoke with the PETAL sub-investigator, Mark Sorial, on “What Is the Optimal Treatment Sequence for Relapsed or Refractory T-Cell Lymphoma?”
Read more
We are thrilled to share that Emmanuel Nwodo has been awarded a prestigious Career Exploration and Development (CXD) grant from Bowdoin College for a 10-week internship with the PETAL Consortium. This grant will support his hands-on research experience with PETAL and culminate in a poster presentation, helping to advance his career in research and data science. Congratulations, Emmanuel!
March, 2025
PETAL Consortium at the TCLF 2025 shared their ongoing projects and work through multiple compelling oral and poster presentations.
We are excited to share that our latest manuscript Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: a global PETAL Consortium study manuscript has been accepted for publication in the British Journal of Haematology.
Read more
February, 2025
MGH the founding site will be participating in the phase III trial of Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma.
Read more
An inspiring story shared by our PETAL patient on how Specialized Expertise Transformed a Critical Setback From Peripheral T-cell Lymphoma Into Hope
Read more
January, 2025
Blood Cancers Today spoke with researchers from the Salvia Jain Lab to learn more about the goals and initiatives of the PETAL Consortium. Leora Boussi, MD, Angela Koh, and Jessy Xinyi Han discuss their study of a novel scoring system using one of the largest international global cohorts of 925 patients with relapsed or refractory mature T-cell and NK-cell lymphomas.
Read more
PETAL has been prominently featured in the MGH Cancer Center Curtain Raiser and the Mass General Brigham Cancer Center newsletter, which reaches over 20,000 individuals across academia, industry, and other fields. We are excited to share key updates on our research with this wide audience.
Read more
We are pleased to share that the University of Pennsylvania (UPenn) is our third participating site which is now active for enrollment
PETAL goes LIVE on social media! As we ramp up our efforts, the PETAL Consortium is now active on Facebook, LinkedIn, Instagram, and Twitter. Follow us for regular updates, insightful resources, and exciting developments in T-cell lymphoma research. Let’s make science accessible and drive meaningful change together.
December, 2024
September, 2024
Mass General Cancer Center organized a 5k Run-Walk where the PETAL team along with the whole Cancer Center was running for a cause. Where we raised awareness and funds to support our research with the help, support and dedication of our patients, families and friends who joined us for a cause.
Read more
June, 2024
Read more
